Aeterna Zentaris Reports Third Quarter 2023 Financial Results - Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to...

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...

Aeterna Zentaris Reports Second Quarter 2023 Financial Results Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency ...

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD) Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...